Heron Therapeutics Share Price Today
(NASDAQ: HRTX)

Name: Heron Therapeutics Share Price Today (NASDAQ: HRTX) - Heron Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Heron Therapeutics share price is $1.65 & ₹143.31 as on 14 Feb 2025, 2.30 'hrs' IST

$1.65

▲

-0.01

(-0.6%)

Market is closed - opens 8 PM, 14 Feb 2025

View live Heron Therapeutics share price in Dollar and Rupees. Guide to invest in Heron Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Heron Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Heron Therapeutics share price movements

Today's Low: $1.62
Today's High: $1.67
$1.65
1.82%
Downside
Day's Volatility :2.99%
Upside
1.2%
52 Weeks Low: $1.04
52 Weeks High: $3.93
$1.65
36.97%
Downside
52 Weeks Volatility :73.54%
Upside
58.02%

Heron Therapeutics (HRTX) Returns

Period	Heron Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	38.66%	1.3%	0.0%
6 Months	-14.51%	-3.5%	0.0%
1 Year	-42.71%	1.6%	0.0%
3 Years	-81.33%	13.6%	-12.5%

Heron Therapeutics (HRTX) Key Statistics

in dollars & INR

Previous Close	$1.66
Open	$1.66
Today's High	$1.67
Today's Low	$1.62
Market Capitalization	$252.5M
Today's Volume	$878.6K
52 Week High	$3.93
52 Week Low	$1.04
Revenue TTM	$137.7M
EBITDA	$-5.7M
Earnings Per Share (EPS)	$-0.16
Profit Margin	-20.31%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-2408.88%

How to invest in Heron Therapeutics Stock (HRTX) from India?

It is very easy for Indian residents to invest directly in Heron Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Heron Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Heron Therapeutics or HRTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Heron Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Heron Therapeutics shares which would translate to 0.526 fractional shares of Heron Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Heron Therapeutics, in just a few clicks!

Returns in Heron Therapeutics (HRTX) for Indian investors in Rupees

The Heron Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Heron Therapeutics investment value today

Current value as on today

₹61,903

Returns

₹38,097

(-38.1%)

Returns from Heron Therapeutics Stock

₹42,708 (-42.71%)

Dollar Returns

₹4,611 (+4.61%)

Indian investors sentiment towards Heron Therapeutics (HRTX)

-28%

Period: Jan 14, 2025 to Feb 13, 2025. Change in 30 Days versus previous period

Search interest for Heron Therapeutics Stock from India on INDmoney has decreased by -28% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Heron Therapeutics

Rubric Capital Management LP
17.56%
Adage Capital Partners Gp LLC
5.82%
Vanguard Group Inc
5.73%
BlackRock Inc
5.61%
Velan Capital Investment Management LP
4.59%
Tejara Capital Ltd
3.49%

Analyst Recommendation on Heron Therapeutics

Buy

90%Buy

10%Hold

0%Sell

Based on 10 Wall street analysts offering stock ratings for Heron Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Heron Therapeutics Stock (HRTX)

What analysts predicted

Upside of 263.64%

Target:

$6.00

Current:

$1.65

Insights on Heron Therapeutics Stock (Ticker Symbol: HRTX)

Price Movement
In the last 3 months, HRTX stock has moved up by 33.1%
Increasing Revenue
Revenue is up for the last 5 quarters, 31.43M → 42.26M (in $), with an average increase of 7.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -9.23M → -4.84M (in $), with an average increase of 90.5% per quarter
HRTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.4% return, outperforming this stock by 100.7%
HRTX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 78.2% return, outperforming this stock by 158.8%
Price to Sales
ForHRTX every $1 of sales, investors are willing to pay $1.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.0 for every $1 of sales.

HRTX Heron Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$77.5M	↑ 151.81%
Net Income	$-178.8M	↓ 9.44%
Net Profit Margin	-230.84%	↑ 411.03%

	FY19	Y/Y Change
Revenue	$146.0M	↑ 88.41%
Net Income	$-204.7M	↑ 14.49%
Net Profit Margin	-140.27%	↑ 90.57%

	FY20	Y/Y Change
Revenue	$88.6M	↓ 39.28%
Net Income	$-224.4M	↑ 9.61%
Net Profit Margin	-253.2%	↓ 112.93%

	FY21	Y/Y Change
Revenue	$86.3M	↓ 2.59%
Net Income	$-217.7M	↓ 3.02%
Net Profit Margin	-252.08%	↑ 1.12%

	FY22	Y/Y Change
Revenue	$107.7M	↑ 24.7%
Net Income	$-134.5M	↓ 38.2%
Net Profit Margin	-124.93%	↑ 127.15%

	FY23	Y/Y Change
Revenue	$127.0M	↑ 17.99%
Net Income	$-110.6M	↓ 17.81%
Net Profit Margin	-87.02%	↑ 37.91%

	Q2 FY23	Q/Q Change
Revenue	$31.8M	↑ 7.25%
Net Income	$-42.1M	↑ 29.52%
Net Profit Margin	-132.42%	↓ 22.77%

	Q3 FY23	Q/Q Change
Revenue	$31.4M	↓ 1.03%
Net Income	$-25.0M	↓ 40.54%
Net Profit Margin	-79.56%	↑ 52.86%

	Q4 FY23	Q/Q Change
Revenue	$34.2M	↑ 8.9%
Net Income	$-10.7M	↓ 57.12%
Net Profit Margin	-31.33%	↑ 48.23%

	Q1 FY24	Q/Q Change
Revenue	$34.7M	↑ 1.28%
Net Income	$-3.2M	↓ 70.53%
Net Profit Margin	-9.11%	↑ 22.22%

	Q2 FY24	Q/Q Change
Revenue	$36.0M	↑ 3.91%
Net Income	$-9.2M	↑ 192.25%
Net Profit Margin	-25.64%	↓ 16.53%

	Q3 FY24	Q/Q Change
Revenue	$42.3M	↑ 17.33%
Net Income	$-4.8M	↓ 47.5%
Net Profit Margin	-11.47%	↑ 14.17%

	FY18	Y/Y Change
Profit	$50.0M	↑ 90.85%

	FY19	Y/Y Change
Profit	$84.3M	↑ 68.83%

	FY20	Y/Y Change
Profit	$52.4M	↓ 37.82%

	FY21	Y/Y Change
Profit	$40.3M	↓ 23.12%

	FY22	Y/Y Change
Profit	$52.8M	↑ 30.93%

	FY23	Y/Y Change
Profit	$61.9M	↑ 17.31%

	Q2 FY23	Q/Q Change
Profit	$11.6M	↓ 9.07%

	Q3 FY23	Q/Q Change
Profit	$13.2M	↑ 13.98%

	Q4 FY23	Q/Q Change
Profit	$24.3M	↑ 84.09%

	Q1 FY24	Q/Q Change
Profit	$26.2M	↑ 7.71%

	Q2 FY24	Q/Q Change
Profit	$25.5M	↓ 2.75%

	Q3 FY24	Q/Q Change
Profit	$23.4M	↓ 8.45%

	FY18	Y/Y Change
Operating Cash Flow	$-191.8M	↑ 12.63%
Investing Cash Flow	$-278.6M	↓ 3699.77%
Financing Cash Flow	$357.6M	↑ 21.75%

	FY19	Y/Y Change
Operating Cash Flow	$-124.6M	↓ 35.05%
Investing Cash Flow	$-21.8M	↓ 92.18%
Financing Cash Flow	$186.4M	↓ 47.87%

	FY20	Y/Y Change
Operating Cash Flow	$-184.8M	↑ 48.35%
Investing Cash Flow	$209.0M	↓ 1059.26%
Financing Cash Flow	$9.1M	↓ 95.12%

	FY21	Y/Y Change
Operating Cash Flow	$-203.4M	↑ 10.03%
Investing Cash Flow	$32.7M	↓ 84.34%
Financing Cash Flow	$156.0M	↑ 1613.65%

	FY22	Y/Y Change
Operating Cash Flow	$-146.9M	↓ 27.76%
Investing Cash Flow	$-3.3M	↓ 110.16%
Financing Cash Flow	$75.1M	↓ 51.89%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-27.2M	↑ 9.1%
Investing Cash Flow	$13.2M	↓ 64.11%
Financing Cash Flow	$319.0K	↓ 253.37%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-9.2M	↓ 66.21%
Investing Cash Flow	$-23.2M	↓ 275.68%
Financing Cash Flow	$53.8M	↑ 16764.26%

Heron Therapeutics Technicals Summary

Sell

Neutral

Buy

Heron Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Heron Therapeutics (HRTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Heron Therapeutics, Inc.	8.55%	-14.51%	-42.71%	-81.33%	-92.19%
Biontech Se	8.01%	44.12%	32.15%	-24.88%	289.28%
Regeneron Pharmaceuticals, Inc.	-4.15%	-42.83%	-29.38%	7.0%	69.56%
Vertex Pharmaceuticals Incorporated	9.03%	-3.1%	8.51%	98.18%	88.09%
Alnylam Pharmaceuticals, Inc.	5.53%	-1.25%	79.67%	72.79%	105.85%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Heron Therapeutics, Inc.	NA	NA	-0.18	-0.12	-24.09	-0.02	NA	-0.26
Biontech Se	160.8	NA	0.04	-3.29	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.32	17.32	0.98	43.2	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.19	18.18	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Heron Therapeutics, Inc.	Buy	$252.5M	-92.19%	NA	-20.31%
Biontech Se	Buy	$27.5B	289.28%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$72.6B	69.56%	17.32	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$116.9B	88.09%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.3B	105.85%	NA	-15.86%

About Heron Therapeutics

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Organization	Heron Therapeutics
Employees	126
CEO	Mr. Craig Alexander Collard
Industry	Health Technology

Management People of Heron Therapeutics

Name	Title
Mr. Craig Alexander Collard	CEO & Director
Ms. Ira Duarte	Executive VP & CFO
Dr. William P. Forbes Pharm. D., Pharm.D.	Executive VP & Chief Development Officer
Mr. Ryan Craig	Vice President of Marketing
Mr. Sean T. Ristine	Senior Vice President of Human Resources
Mr. Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations
Mr. Brett Fleshman	Chief Business Officer
Mr. Jeff Cohn J.D.	Executive Director, Assistant General Counsel & Assistant Secretary

Important FAQs about investing in HRTX Stock from India :

What is Heron Therapeutics share price today?

Heron Therapeutics share price today stands at $1.65, Open: $1.66 ; Previous Close: $1.66 ; High: $1.67 ; Low: $1.62 ; 52 Week High: $3.93 ; 52 Week Low: $1.04.

The stock opens at $1.66, after a previous close of $1.66. The stock reached a daily high of $1.67 and a low of $1.62, with a 52-week high of $3.93 and a 52-week low of $1.04.

Can Indians buy Heron Therapeutics shares?

Yes, Indians can invest in the Heron Therapeutics (HRTX) from India.

With INDmoney, you can buy Heron Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Heron Therapeutics at zero transaction cost.

How can I buy Heron Therapeutics shares from India?

It is very easy to buy Heron Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Heron Therapeutics (HRTX) be purchased?

Yes, you can buy fractional shares of Heron Therapeutics with INDmoney app.

What are the documents required to start investing in Heron Therapeutics stocks?

To start investing in Heron Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.